Working… Menu
Trial record 5 of 19 for:    "Aspergillosis" | "Amphotericin B"

Value of Amphotericin B Inhalation for Prophylaxis of Invasive Pulmonary Aspergillosis After Renal Transplantation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00986713
Recruitment Status : Unknown
Verified September 2009 by Capital Medical University.
Recruitment status was:  Recruiting
First Posted : September 30, 2009
Last Update Posted : September 30, 2009
Information provided by:
Capital Medical University

Brief Summary:
The purpose of this study is to determine whether inhalation with aerosolized amphoterin B 10mg/d is more effective than aerosolized amphoterin B 2mg/d to reduce the incidence of invasive pulmonary aspergillosis.

Condition or disease Intervention/treatment Phase
Invasive Pulmonary Aspergillosis Drug: Amphotericin B Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 400 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Prevention
Study Start Date : June 2008
Estimated Primary Completion Date : September 2010
Estimated Study Completion Date : October 2010

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Aspergillosis

Intervention Details:
  • Drug: Amphotericin B
    Aerosolized Amphotericin B,2mg/day or 10mg/day

Primary Outcome Measures :
  1. invasive pulmonary aspergillosis [ Time Frame: 3 years ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • 65ys≥age≥18ys
  • renal transplant recipients

Exclusion Criteria:

  • subjects with hypersensitivity to amphotericin B
  • receipt of inhalational or intravenous amphotericin B within last 30 days
  • subjects with known invasive fungal infection before renal transplant
  • subjects with pneumonia

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00986713

Layout table for location information
China, Beijing
Beijing Chaoyang Hospital,Affiliate of Capital Medical University Recruiting
Beijing, Beijing, China, 100020
Contact: Bin Cao, doctor    8610-85231130   
Sponsors and Collaborators
Capital Medical University

Layout table for additonal information
Responsible Party: Bin Cao,doctor, Beijing Chaoyang Hospital,Affiliate of Capital Medical Unibersity Identifier: NCT00986713     History of Changes
Other Study ID Numbers: CYH-CMU AmB Neph
First Posted: September 30, 2009    Key Record Dates
Last Update Posted: September 30, 2009
Last Verified: September 2009
Additional relevant MeSH terms:
Layout table for MeSH terms
Pulmonary Aspergillosis
Invasive Pulmonary Aspergillosis
Amphotericin B
Liposomal amphotericin B
Lung Diseases, Fungal
Lung Diseases
Respiratory Tract Diseases
Invasive Fungal Infections
Antiprotozoal Agents
Antiparasitic Agents
Anti-Infective Agents
Anti-Bacterial Agents
Antifungal Agents